Utama › Kanser Perut › Pennsylvania › Pittsburgh
Kajian klinikal Kanser Perut di Pittsburgh, PA
14 kajian untuk Kanser Perut sedang mencari peserta di lokasi dalam dan sekitar Pittsburgh (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Distance-Based Exercise to Preserve Function and Prevent Disability
Mengambil peserta
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Mengambil pesertaFasa 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Mengambil pesertaFasa 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Mengambil pesertaFasa 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Mengambil pesertaFasa 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Mengambil pesertaFasa 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Mengambil pesertaFasa 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Mengambil pesertaFasa 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Mengambil pesertaFasa 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Mengambil pesertaFasa 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Mengambil pesertaFasa 1
- AHN West Penn Hospital, Pittsburgh
Kajian Kanser Perut di bandar lain
- Houston, TX42 kajian
- Boston, MA32 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Baldwin Park, CA22 kajian
- Los Angeles, CA22 kajian
- Arlington, VA20 kajian
- Dallas, TX19 kajian
- San Antonio, TX19 kajian
- St. Louis, MO18 kajian
- Grand Rapids, MI18 kajian
- Washington, DC16 kajian
Kajian lain di Pittsburgh
- Kanser Paru-paru Bukan Sel Kecil48 kajian
- Kanser (semua jenis)41 kajian
- Kanser Payudara39 kajian
- Kanser Kolorektal32 kajian
- Kanser Metastatik31 kajian
- Melanoma31 kajian
- Kanser Ovari30 kajian
- Kanser Endometrium23 kajian
- Kanser Prostat23 kajian
- Kanser Paru-paru23 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher22 kajian
- Strok22 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.